Skip to main content
. 2016 Aug 16;7(36):58516–58530. doi: 10.18632/oncotarget.11305

Figure 3. DSF/Cu inhibits ALDH-positive NSCLC stem cells in vivo.

Figure 3

A. DSF/Cu decreases the size of tumors derived from ALDH-positive NSCLC xenografts. Images of the tumors that developed in NOD/SCID mice from each treatment group are also shown. (*P < 0.05, one-way ANOVA). B. DSF/Cu has no apparent toxicity as determined by body weight. C. Representative images of immunohistochemical staining of tumor tissue for the stem cell transcription factors Nanog and Oct-4. The staining intensity was scored as 0 (negative), 1 (weak), 2 (medium) and 3 (strong). Extent of staining was scored as 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) and 4 (76-100%), according to the percentage of the positively stained areas in relation to the whole carcinoma area (*P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA).